JPMorgan ups Ross Stores target, adds to Analyst Focus List
Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M
Charlie Munger Says His Financial Success Came From These 'Tricks' He 'Got Into By Accident in Life'
Gilead price target raised to $154 from $144 at BofA
Experts believe Washington 'must break its promise on Social Security' to protect it from 'imminent insolvency'
'Gray divorce’ is up 40% as more couples over 50 split, leaving many without a safety net. Here's how to stay protected
FineHeart secures €83m to advance cardiac device development
Private Credit’s Biggest BDCs Grappling With Investor Exodus
- Politics tops Americans' list of money fears, financial planners say. How you can protect yourself
- S&P 500 Is on Track for a New Closing High
- Best 6-month CD rates for January 2026: Earn up to 4.05% APY
- Treasury Secretary Scott Bessent Touts Trump's $10K Tax Deduction On Auto Loans For 2025-2028 US-Made Vehicles: 'Putting Money Back In...'
- Energy Transfer (ET) Halts the Development of Lake Charles LNG Facility
- Analyst Reinstates Coverage of Cenovus Energy (CVE) with ‘Buy’ Rating
- Analyst Lowers Price Target on Canadian Natural Resources (CNQ) to $35
- Analyst Reiterates ‘Buy’ Rating on Devon Energy (DVN)
- Occidental Petroleum (OXY) Closes Sale of Chemical Business to Berkshire Hathaway
- Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week’s Business Updates

